Clinical pharmacology of cytotoxic drugs in neonates and infants: Providing evidence-based dosing guidance

A Laura Nijstad, Shelby Barnett, Arief Lalmohamed, Inez M Bérénos, Elizabeth Parke, Vickyanne Carruthers, Deborah A Tweddle, Jordon Kong, C Michel Zwaan, Alwin D R Huitema, Gareth J Veal

Research output: Contribution to journalReview articlepeer-review

Abstract

Cancer in neonates and infants is a rare but challenging entity. Treatment is complicated by marked physiological changes during the first year of life, excess rates of toxicity, mortality, and late effects. Dose optimisation of chemotherapeutics may be an important step to improving outcomes. Body size-based dosing is used for most anticancer drugs used in infants. However, dose regimens are generally not evidence based, and dosing strategies are frequently inconsistent between tumour types and treatment protocols. In this review, we collate available pharmacological evidence supporting dosing regimens in infants for a wide range of cytotoxic drugs. A systematic review was conducted, and available data ranked by a level of evidence (1-5) and a grade of recommendation (A-D) provided on a consensus basis, with recommended dosing approaches indicated as appropriate. For 9 of 29 drugs (busulfan, carboplatin, cyclophosphamide, daunorubicin, etoposide, fludarabine, isotretinoin, melphalan and vincristine), grade A was scored, indicating sufficient pharmacological evidence to recommend a dosing algorithm for infants. For busulfan and carboplatin, sufficient data were available to recommend therapeutic drug monitoring in infants. For eight drugs (actinomycin D, blinatumomab, dinutuximab, doxorubicin, mercaptopurine, pegaspargase, thioguanine and topotecan), some pharmacological evidence was available to guide dosing (graded as B). For the remaining drugs, including commonly used agents such as cisplatin, cytarabine, ifosfamide, and methotrexate, pharmacological evidence for dosing in infants was limited or non-existent: grades C and D were scored for 10 and 2 drugs, respectively. The review provides clinically relevant evidence-based dosing guidance for cytotoxic drugs in neonates and infants.

Original languageEnglish
Pages (from-to)137-154
Number of pages18
JournalEuropean Journal of Cancer
Volume164
DOIs
Publication statusPublished - Mar 2022

Keywords

  • Antineoplastic Agents/adverse effects
  • Antineoplastic Combined Chemotherapy Protocols/therapeutic use
  • Busulfan
  • Carboplatin
  • Etoposide
  • Humans
  • Infant
  • Infant, Newborn

Fingerprint

Dive into the research topics of 'Clinical pharmacology of cytotoxic drugs in neonates and infants: Providing evidence-based dosing guidance'. Together they form a unique fingerprint.

Cite this